Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

Presentation TCT 2022

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Presenter: Pablo Salinas

September 19, 2022

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

Presentation TCT 2022

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Presenter: Gustavo Araújo

September 17, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Advertisement

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

TCTMD’s Top 10 Most Popular Stories for March 2022

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content